Seeking Alpha

Celgene's (CELG +0.8%) pomalidomide, in combination with a low dose of the steroid...

Celgene's (CELG +0.8%) pomalidomide, in combination with a low dose of the steroid dexamethasone, helped patients with multiple myeloma live a median 3.6 months without their disease worsening in a Phase III study. That's above the 1.8 months for the blood cancer patients taking just a high dose of the steroid. The FDA is due to decide whether to approve pomalidomide by Feb 10. Analysts reckon pomalidomide could generate sales of over $1B/year by 2017. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs